Folic Acid-Functionalized MWCNT-Conjugated Zirconium Oxide Nanoparticles for Targeted Cancer Cell Delivery of Astaxanthin

초록

In this study, zirconium oxide nanoparticles (ZrO2 NPs) were synthesized using astaxanthin (AST) rich extract (AZ) and subsequently conjugated with multiwalled carbon nanotubes (MWCNTs) (AZM) and functionalized with folic acid (FA) (FAZM) to develop a cancer-targeting nanocomposite with enhanced anticancer efficacy. The physicochemical properties of the synthesized materials were characterized using transmission electron microscopy (TEM), dynamic light scattering (DLS), electrophoretic light scattering (ELS), X-ray diffraction (XRD), and Fourier transform infrared spectroscopy (FT-IR). FAZM exhibited the highest antioxidant activity, with IC50 values of 822.78 mu g/mL against ABTS and 320.70 mu g/mL against DPPH free radicals. Biocompatibility assessments revealed that FAZM exhibited little cytotoxicity in normal human skin cells and demonstrated improved hemocompatibility, as confirmed by a hemolysis assay. Furthermore, FAZM significantly inhibited the proliferation of MDA-MB-231 breast cancer cells, inducing apoptosis and exhibiting potent cytotoxic effects (IC50: 115.84 mu g/mL). These findings suggest that FA and MWCNTs enhance the cancer-targeting capability of AZ while maximizing its selective cytotoxicity against cancer cells. This study highlights that FA-functionalized MWCNT-conjugated ZrO2 NPs are a promising nanoplatform as an AST delivery system for targeted cancer therapy.

키워드